Exclusive synbio future panel & networking cocktail
✨ Opening Bioweek ✨
Genopole, Newfund, XAnge and RAISE Sherpas join forces for an electrifying evening event, just before iGem festivities, as we dive into the futuristic vision of synthetic biology and its potential to revolutionize our world.
Expect a relaxed fireside chat featuring top voices in synthetic biology :
▪️Andrew Hessel: Biotech entrepreneur & co-founder of GP-write
▪️Antoniya G.: Synthetic biology researcher, PhD, Founder of Biogaria, award-winning scientist.
▪️Carlos Silveira: Biofuturist & Biodesign thought leader.
Join provocative debates on ethics, design, philosophy and explore how synthetic biology could revolutionize medicine, agriculture, energy, materials and environmental sustainability by 2050.
The future is biological. Be there as we redefine it.
About Genopole:
A French biocluster dedicated to genetic research and biotechnologies applied to health and the environment, Genopole brings together 78 companies, 16 academic research laboratories, 23 technology platforms and university training courses (University of Evry, Paris Saclay).
Its aim is to encourage the emergence and growth of biotechnology companies, the transfer of innovations to the industrial sector, and the development of research and higher education in the life sciences.
Headed by Gilles Trystram, Genopole is mainly supported by the French government, the Ile de-France Region, the Essonne Department, the Grand Paris Sud conurbation, the town of Evry-Courcouronnes and the AFM-Téléthon.
https://www.genopole.com/
About Newfund:
Newfund is an early-stage venture capital firm supporting bold entrepreneurs with global ambitions. From the seed stage through international expansion, startups receive long-term backing reinforced by sustained follow-on investments.
With €400M under management and a 25-person team across Paris, Silicon Valley, and Nouvelle-Aquitaine, Newfund currently holds a portfolio of more than 120 innovative companies. It is supported by a unique investor base of entrepreneurs and family offices — the largest of its kind in France for an innovation fund.
HealthTech is a strategic priority, backed by a dedicated fund for the sector. Newfund's portfolio includes Raidium (medical imaging), Oria Bioscience (TechBio), Cuure (nutrition), Diagnoly (screening), Arkhn (infrastructure), and Omnidoc (care pathways).
About XAnge:
XAnge is a European venture capital firm with over 20 years of experience, based in Paris, Berlin, and Brussels. As the innovation-focused venture arm of the Siparex Group, XAnge backs early-stage founders creating transformational solutions that deliver lasting value for society and business.
With €700M under management, XAnge invests from seed to Series B and has a strong track record in HealthTech, Deep Tech, SaaS, and AI. Health is a strategic focus, supported by XAnge 4 and Mutuelles Impact, which invest in companies improving healthcare access, quality of life, social care and environmental health.
The health portfolio includes Treefrog Therapeutics, Epigene Labs, Qubit Pharmaceuticals (Biotech) and Implicity, Gleamer, Diagnoly, SurgAR, Synapse (Digital health).
About RAISE Sherpas:
The RAISE Sherpas endowment fund is the first philanthropic accelerator dedicated to supporting impact-driven initiatives. With a budget of €67 million — including €32 million funded through the innovative allocation of 50% of the carried interest from RAISE Group’s investment teams — RAISE Sherpas finances, supports, and connects French startups and European non-profits as they scale and grow their impact.